Revance Therapeutics Inc (RVNC) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The companys product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis among others. It also provides RT001, a topical gel formulation of daxibotulinumtoxinA, which is designed to eliminate the use of needles. Revance Therapeutics develops products for multiple aesthetic and therapeutic applications. The company utilizes TransMTS platform technology for the development of its products. It offers products for dermatology, neurology, musculoskeletal disorders, urology and ophthalmology. Revance Therapeutics is headquartered in Newark, California, the US.

Revance Therapeutics Inc (RVNC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12
Venture Financing 13
Revance Therapeutics Raises US$10 Million In Venture Financing 13
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 14
Licensing Agreements 16
Mylan Enters into Licensing Agreement with Revance Therapeutics 16
Equity Offering 17
Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17
Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18
Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20
Revance Therapeutics Raises USD134.6 Public Offering of Shares 21
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24
Revance Therapeutics Completes IPO For US$110.4 Million 26
Revance Therapeutics Inc - Key Competitors 28
Revance Therapeutics Inc - Key Employees 29
Revance Therapeutics Inc - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
May 08, 2018: Revance Releases First Quarter 2018 Results 31
Feb 28, 2018: Revance Announces Fourth Quarter and Full Year 2017 Financial Results 32
Nov 02, 2017: Revance Releases Third Quarter 2017 Results 33
Aug 03, 2017: Revance Releases Second Quarter 2017 Results 34
May 09, 2017: Revance Releases First Quarter 2017 Results 35
Feb 27, 2017: Revance Releases Fourth Quarter and Full Year 2016 Results 36
Corporate Communications 38
May 09, 2018: Revance Therapeutics Announces Two Recent Additions to Its Management Team 38
May 01, 2018: Revance Therapeutics Appoints Caryn McDowell As SVP, General Counsel & Corporate Secretary 39
Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors 40
Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics 41
Product News 42
01/12/2017: Revance Therapeutics Enters into $6.4M Settlement with City of Warren Police and Fire Retirement System 42
Clinical Trials 43
Jun 05, 2017: Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial 43
May 18, 2017: Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial 45
May 01, 2017: Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis 47
Mar 07, 2017: Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 48
Mar 03, 2017: Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting 49
Jan 26, 2017: BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 50
Jan 18, 2017: Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017 51
Jan 05, 2017: Revance Provides Clinical Milestones and Financial Outlook for 2017 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List Of Tables

List of Tables
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12
Revance Therapeutics Raises US$10 Million In Venture Financing 13
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 14
Mylan Enters into Licensing Agreement with Revance Therapeutics 16
Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17
Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18
Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20
Revance Therapeutics Raises USD134.6 Public Offering of Shares 21
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24
Revance Therapeutics Completes IPO For US$110.4 Million 26
Revance Therapeutics Inc, Key Competitors 28
Revance Therapeutics Inc, Key Employees 29
Revance Therapeutics Inc, Subsidiaries 30

List Of Figures

List of Figures
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cerevance Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cerevance Inc (Cerevance) is a pharmaceutical company that strives to develop medicines for the treatment of neurological and psychiatric diseases. It is also developing preclinical and clinical programs for Parkinsons

USD 250 View Report

Revance Therapeutics Inc (RVNC) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The companys product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of

USD 250 View Report

Anika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2019 Update

Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for tissue protection, repair and regeneration. It offers solutions for orthobiologics, dermal, ophthalmic, surgical and veterinary applications. Its major products

USD 750 View Report

Pear Therapeutics Inc - Product Pipeline Analysis, 2019 Update

Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD)

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available